August - 2020

top of page

Sage Group News

Sage Represents Respira Therapeutics - Opportunity to License RT234, A Late Stage Asset for Pulmonar

The Sage Group is working with Respira Therapeutics (“Respira”; http://respiratherapeutics.com/) to identify clinical and commercial...

Sage Represents DBM: An Opportunity to Acquire or Partner with a Revenue Generating Pre-Clinical CRO

The Sage Group is pleased to announce it is representing Discovery Biomed (“DBM”; https://discoverybiomed.com/). DBM is a...

bottom of page